Arbutus Biopharma Corp (ABUS) vs Odyssey Therapeutics, Inc. (ODTX)

A side-by-side comparison of Arbutus Biopharma Corp and Odyssey Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Arbutus Biopharma Corp logo
ABUS
Arbutus Biopharma Corp
$906M
$4.59HealthcareDelayed quote: Oct 6, 2026, 11:31 AM EDT
Odyssey Therapeutics, Inc. logo
ODTX
Odyssey Therapeutics, Inc.
$948M
$19.74HealthcareDelayed quote: Oct 6, 2026, 11:25 AM EDT

Total return — ABUS vs ODTX

growth of $100 · dividends reinvested · last 1y
ABUS +7.4% (+7.4%/yr)ODTX +26.9% (+26.9%/yr)ODTX compounded faster over this window
100120140160180Start $100$107$127
ABUS ODTX

ABUS vs ODTX: by the numbers

  • •ODTX is the larger company ($948M vs $906M market cap).
  • •ABUS is profitable (84.23% net margin) while ODTX runs a net loss (-4994.86%).

Metrics side by side

Valuation

MetricABUSODTX
P/E ratio5.88N/A
Forward P/E6.20N/A
P/S ratio4.99N/A
P/B ratio3.502.25
EV / EBITDA6.05N/A

Profitability

MetricABUSODTX
Gross margin99.98%100.00%
Operating margin-192.08%-5415.19%
Net margin84.23%-4994.86%
ROE59.16%N/A
ROIC54.39%-66.23%

Growth (annualized)

MetricABUSODTX
Revenue CAGR (5Y)85.17%N/A
Total return CAGR (5Y)2.19%N/A

Frequently asked

Is ABUS or ODTX more profitable?
ABUS runs the higher net margin — ABUS at 84.23% versus ODTX at -4994.86%.

Go deeper

Full ABUS analysisFull ODTX analysisInteractive comparison tool

Dig into the metrics

Arbutus Biopharma P/E ratioArbutus Biopharma ROEOdyssey Therapeutics ROEArbutus Biopharma operating marginOdyssey Therapeutics operating marginArbutus Biopharma revenue growthOdyssey Therapeutics revenue growthArbutus Biopharma free cash flowOdyssey Therapeutics free cash flow

Arbutus Biopharma & Odyssey Therapeutics appear in these rankings

Fastest Revenue Growth StocksHighest ROE StocksHighest ROIC StocksLowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.